In this regard, small molecule NIK inhibitors are being developed and have been shown to be protective in liver injury and fibrosis, lymphoma, melanoma, and systemic lupus erythematosus in preclinical models [14,20,21,22,23,24,25,26,27]. This evidence concerns the gene MAP3K14 and lymphoma.